stockportfolio.pro
Stocks / ASTH vs OCUL
ASTH vs OCUL
Astrana Health, Inc. and Ocular Therapeutix, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Astrana Health, Inc. (ASTH) | Ocular Therapeutix, Inc. (OCUL) | |
|---|---|---|
| Market cap | $1.9B | $1.9B |
| Revenue (latest FY) | $3.18B | $51.95M |
| Net income (latest FY) | $22.49M | $-265.94M |
| Revenue growth (5y CAGR) | 35.9% | 24.4% |
| Net margin | 0.7% | -511.9% |
| Return on equity | 2.9% | -40.6% |
| P/E ratio | 62.6 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ASTH — free Open OCUL — freeFrequently asked questions
Which is bigger, ASTH or OCUL?
Ocular Therapeutix, Inc. is larger by market capitalization — $1.9B versus $1.9B.
Which grows faster, ASTH or OCUL?
Over the last five fiscal years, Astrana Health, Inc. grew revenue faster — 35.9%/yr versus 24.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.